{"id":"W2746091303","doi":"10.1200/jco.2017.73.0226","title":"Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor–Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Thyroid Cancer Diagnosis and Treatment","field":"Medicine","cited_by":130,"is_retracted":false,"has_abstract":true,"ca_institutions":"Amgen (Canada)","funders":"National Cancer Institute","keywords":"Medicine; Cabozantinib; Lenvatinib; Pazopanib; Sorafenib; Internal medicine; Response Evaluation Criteria in Solid Tumors; Medullary thyroid cancer; Oncology; Thyroid cancer; Sunitinib; Refractory (planetary science); Tyrosine-kinase inhibitor; Adverse effect; Population; Axitinib; Cancer; Clinical trial; Phases of clinical research; Hepatocellular carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001392314,0.0003099881,0.002085987,0.0001745201,0.0001942612,0.00002838135,0.00044207,0.0004619103,0.0001148993],"category_scores_gemma":[0.002939384,0.0001928187,0.0007204661,0.00005592193,0.0004263362,0.0002572808,0.0001226217,0.0007167943,0.000002832845],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003829476,"about_ca_system_score_gemma":0.001428862,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001998655,"about_ca_topic_score_gemma":0.0002371818,"domain_scores_codex":[0.9953673,0.0002962684,0.002954445,0.0004202342,0.0006122402,0.0003494674],"domain_scores_gemma":[0.9897362,0.001684649,0.006362532,0.0004871899,0.001315417,0.0004140169],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6829194,0.0590102,0.03597446,0.0000193724,0.001765401,0.0001913143,0.00017743,0.000001183028,0.001358522,0.00003340879,0.005805125,0.2127442],"study_design_scores_gemma":[0.4993512,0.2526334,0.1443651,0.0002176113,0.0005713728,0.000009947908,0.00003167822,0.00001463763,0.0009414165,0.00003426702,0.1016971,0.0001321836],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9838909,0.0008549328,0.00003152212,0.007458684,0.005485571,0.001491763,0.000292599,0.00001157907,0.0004824733],"genre_scores_gemma":[0.9895232,0.005117395,0.001026678,0.0009940715,0.002921202,0.000105538,0.0001047792,0.00004202405,0.0001651289],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.212612,"threshold_uncertainty_score":0.786292,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07839486005662127,"score_gpt":0.4642816191764927,"score_spread":0.3858867591198714,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}